These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 22550965)

  • 21. Current Treatment Options for Osteoarthritis.
    Hermann W; Lambova S; Muller-Ladner U
    Curr Rheumatol Rev; 2018; 14(2):108-116. PubMed ID: 28875826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New horizons in osteoarthritis.
    Oliviero F; Ramonda R; Punzi L
    Swiss Med Wkly; 2010; 140():w13098. PubMed ID: 20458653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OA clinical trials: current targets and trials for OA. Choosing molecular targets: what have we learned and where we are headed?
    Hellio Le Graverand-Gastineau MP
    Osteoarthritis Cartilage; 2009 Nov; 17(11):1393-401. PubMed ID: 19426849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of osteoarthritis with anakinra.
    Iqbal I; Fleischmann R
    Curr Rheumatol Rep; 2007 Apr; 9(1):31-5. PubMed ID: 17437664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigational drugs for the treatment of osteoarthritis, an update on recent developments.
    Zhu Z; Li J; Ruan G; Wang G; Huang C; Ding C
    Expert Opin Investig Drugs; 2018 Nov; 27(11):881-900. PubMed ID: 30345826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy.
    Chevalier X; Conrozier T; Richette P
    Arthritis Res Ther; 2011 Aug; 13(4):124. PubMed ID: 21888686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study.
    Chevalier X; Giraudeau B; Conrozier T; Marliere J; Kiefer P; Goupille P
    J Rheumatol; 2005 Jul; 32(7):1317-23. PubMed ID: 15996071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modalities for reducing interleukin 1 activity in disease.
    Dinarello CA
    Trends Pharmacol Sci; 1993 May; 14(5):155-9. PubMed ID: 8212310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of genotypes affecting the expression of interleukin-1beta or interleukin-1 receptor antagonist with osteoarthritis.
    Moos V; Rudwaleit M; Herzog V; Höhlig K; Sieper J; Müller B
    Arthritis Rheum; 2000 Nov; 43(11):2417-22. PubMed ID: 11083263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics.
    Oo WM; Yu SP; Daniel MS; Hunter DJ
    Expert Opin Emerg Drugs; 2018 Dec; 23(4):331-347. PubMed ID: 30415584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage.
    Abramson SB; Amin A
    Rheumatology (Oxford); 2002 Sep; 41(9):972-80. PubMed ID: 12209029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Astragaloside inhibits IL-1β-induced inflammatory response in human osteoarthritis chondrocytes and ameliorates the progression of osteoarthritis in mice.
    Li H; Peng Y; Wang X; Sun X; Yang F; Sun Y; Wang B
    Immunopharmacol Immunotoxicol; 2019 Aug; 41(4):497-503. PubMed ID: 31293216
    [No Abstract]   [Full Text] [Related]  

  • 33. The interleukin 1beta pathway in the pathogenesis of osteoarthritis.
    Daheshia M; Yao JQ
    J Rheumatol; 2008 Dec; 35(12):2306-12. PubMed ID: 18925684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of the risk of osteoarthritis with high innate production of interleukin-1beta and low innate production of interleukin-10 ex vivo, upon lipopolysaccharide stimulation.
    Riyazi N; Slagboom E; de Craen AJ; Meulenbelt I; Houwing-Duistermaat JJ; Kroon HM; van Schaardenburg D; Rosendaal FR; Breedveld FC; Huizinga TW; Kloppenburg M
    Arthritis Rheum; 2005 May; 52(5):1443-50. PubMed ID: 15880595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy.
    Pelletier JP; Caron JP; Evans C; Robbins PD; Georgescu HI; Jovanovic D; Fernandes JC; Martel-Pelletier J
    Arthritis Rheum; 1997 Jun; 40(6):1012-9. PubMed ID: 9182910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modalities for reducing interleukin 1 activity in disease.
    Dinarello CA
    Immunol Today; 1993 Jun; 14(6):260-4. PubMed ID: 8397767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-1 in disease.
    Dinarello CA
    Keio J Med; 1994 Sep; 43(3):131-6. PubMed ID: 7967307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sinomenine contributes to the inhibition of the inflammatory response and the improvement of osteoarthritis in mouse-cartilage cells by acting on the Nrf2/HO-1 and NF-κB signaling pathways.
    Wu Y; Lin Z; Yan Z; Wang Z; Fu X; Yu K
    Int Immunopharmacol; 2019 Oct; 75():105715. PubMed ID: 31310911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repurposing drugs for the treatment of osteoarthritis.
    Kuswanto W; Baker MC
    Osteoarthritis Cartilage; 2024 Aug; 32(8):886-895. PubMed ID: 38821468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical review of chondroitin sulfate in osteoarthritis.
    Uebelhart D
    Osteoarthritis Cartilage; 2008; 16 Suppl 3():S19-21. PubMed ID: 18674931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.